ArticlePrzeglad gastroenterologiczny2026
Remission duration according to dietary adherence in paediatric mild to moderate Crohn's disease treated with CDED + PEN.
Article in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Crohn's Disease Exclusion Diet (CDED) combined with partial enteral nutrition (PEN) is a dietary therapy developed to induce and maintain remission in patients with Crohn's disease. Aim: The aim of study was to evaluate the duration of clinical remission in paediatric patients with mild to moderate Crohn's disease undergoing a Crohn's Disease Exclusion Diet (CDED) combined with partial enteral nutrition (PEN), stratified by degree of dietary adherence. Material and methods: A retrospective, single-centre observational study was conducted with the participation of paediatric patients who underwent CDED + PEN treatment in the period from June 2019 to June 2025. Twelve-month clinical follow-up was available in 41 subjects. The following were assessed: BMI-SDS index (group 6-17 years), erythrocyte sedimentation rate, C-reactive protein, faecal calprotectin, Pediatric Crohn's Disease Activity Index (PCDAI) scale score, and adherence. Time to relapse was analysed. Results: Data from 54 patients aged 6-17 years were analysed. Mean baseline PCDAI was 15.47 ±12.44. Clinical remission (PCDAI < 10) was achieved in 69% at week 6 and in 77% at week 12. The median time to relapse was 8.2 months. A statistically significant factor influencing the duration of remission was identified. The median remission time was 11.97 months (IQR: 7.60-25.98; mean: 18.75 ±16.18) in patients with adherence ≥ 80% ( Conclusions: Suboptimal adherence remains a key modifiable predictor of relapse. Data support consideration of CDED + PEN as a viable long-term strategy in motivated families and underscore the pivotal role of the dietitian in monitoring adherence and nutritional status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.